NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets liver fat in MASH: early trial begins
Disease control Recruiting nowThis early-phase study tests a drug called miricorilant in 8 adults with MASH, a fatty liver disease linked to metabolism. The goal is to see if the drug can lower fat production in the liver over 6 weeks. Participants take the drug and have imaging and blood tests to measure cha…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 17, 2026 14:00 UTC
-
New drug shows promise for fatty liver in early trial
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive either the drug or a placebo to see if it safely reduces liver fat over 24 weeks. The goal is to find a new treatment that controls…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Polaris Group • Aim: Disease control
Last updated May 15, 2026 11:56 UTC